What does BoomRx pricing mean for a clinic P&L?

You can plan the structure: which SKUs drive volume, expected refill cadence, and the patient price points your market supports. What you cannot plan up front with BoomRx is the COGS number itself, because per-vial rates are not public. That gap matters most for high-volume GLP-1 programs, where a small per-vial difference multiplied across hundreds of monthly refills swings the bottom line — and where a $30 shipping fee per patient order adds a fixed cost that scales with order count, not vial count. Before margin depends on it, ask for written per-vial cost on your top three SKUs and confirm whether the rate is fixed or subject to change at volume tiers.

Also clarify how ancillary costs hit the P&L. If payment processing or a platform fee are billed separately from the dashboard drug rate, the quoted line understates true landed cost. Add the $30 flat shipping fee per patient order to your model and spread it across the vials in a typical order so your margin model uses the all-in number per vial delivered, not the headline rate.

Fizy Health is the same category but inverts the planning problem. It shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a separately disclosed facilitation fee at payment. For a P&L, that means COGS is a number you can read before you commit, so you can set patient pricing and project gross margin from day one instead of after signup.

Building the whole refill day in one cart reinforces the model: each line shows its cost, so you can see total COGS for a batch and the margin it implies before you submit a single payment. Owners who manage to a target gross margin get a faster, cleaner loop — see cost, set price, confirm spread — without waiting on a portal to fill in the most important line on the page.